11 stories found
Multiple companies, including Greystone Housing Impact, Elbit Systems, and Tencent Music Entertainment, have announced their Q2 2026 earnings previews. Other companies like Geodrill and AG Mortgage Investment Trust have released highlights from their Q2 earnings calls.
Several companies, including AVITA Medical, Xos, and Gambling.com, have released their latest quarterly earnings reports, with some beating and others missing analyst expectations. Additionally, JBT Marel and Kimberly-Clark declared quarterly dividends, while analysts offered insights on various healthcare companies.
An analysis suggests that Autolus Therapeutics (AUTL) could be one of the best biotech penny stocks to consider buying in 2026.
Legence announced its latest financial results, reporting a GAAP EPS of -$0.55, which missed analyst estimates by $0.59, but its revenue of $737.64 million surpassed expectations by $118.33 million.
Geron (GERN) and Autolus Therapeutics (AUTL) have both granted inducement stock options to their new employees. These awards are part of their compensation packages to attract new talent.
Autolus Therapeutics and BioHarvest Sciences have both released their first-quarter earnings reports and held investor calls. The reports highlight their financial performance and key developments for the quarter.
Baird, a financial services firm, has reduced its price target for Nyxoah SA (NYXH) shares from $5.87 to $4.62. This adjustment reflects a revised outlook on the company's financial performance or market conditions.
Autolus Therapeutics has released a preview of its financial performance for the fiscal year 2025.
Autolus Therapeutics (AUTL) is shedding its speculative status as revenue from its drug AUCATZYL continues to grow.
Several companies, including LogicMark, NKT A/S, and Intuitive Machines, have released or previewed their quarterly financial results. These reports detail earnings per share, revenue, and provide transcripts or summaries of earnings calls for Q1 2026, Q1 2025, and Q2 2025.
Humacyte reported its Q4 GAAP EPS of -$0.13, which was in-line with expectations, but its revenue of $0.47 million missed estimates, with further details emerging from its earnings call.